Boehringer Ingelheim

Found 2253 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Boehringer Ingelheim"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Pegylated interferon
Drug: Ribavirin

First Posted Date: 2014-10-09

Last Posted Date: 2025-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02259855

Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: KUC 7483 CL
Other: High fat meal

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT02259907

Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan/amlodipine fixed-dose combination (FDC) tablet
Drug: Telmisartan
Drug: Amlodipine

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02259803

Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 1744 CL
Drug: Tiotropium bromide

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02259946

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Single rising doses of BI 1744 CL, solution for oral inhalation
Drug: Placebo
Drug: Tiotropium, fixed dose, solution for oral inhalation

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02259959

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Persantin® commercial formulation
Drug: Persantin® new formulation

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02259998

Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Medium dose of BIBT 986 CL, per i.v. infusion
Drug: High dose of BIBT 986 CL, per i.v. infusion
Drug: Placebo
Drug: Low dose of BIBT 986 CL, per i.v. infusion
Drug: Lipopolysaccharide (LPS), single i.v. bolus

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02259881

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 113823 solution
Drug: BI 113823 tablet
Other: High fat, high calorie breakfast

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63

Registration Number: NCT02259972

Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: WAL 801 CL dry syrup new formulation
Drug: WAL 801 CL dry syrup conventional formulation

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02260050

Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Epinastine tablets
Drug: Epinastine syrup

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02260063

AI-Powered Research

Premium Access

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male Volunteers

Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers

Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers

Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers